Evercore ISI analyst Vijay Kumar raised the firm’s price target on Boston Scientific (BSX) to $113 from $110 and keeps an Outperform rating on the shares following quarterly results. The firm says that Street fears around EP share losses had dominated the narrative heading into print. EP beat and served to allay fear. Shares are up above 5%, which Evercore believes seems appropriate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Morning Movers: GE Vernova climbs after third quarter earnings
- Boston Scientific raises FY25 adjusted EPS view to $3.02-$3.04 from $2.95-$2.99
- Boston Scientific reports Q3 adjusted EPS 75c, consensus 71c
- Boston Scientific sees Q4 adjusted EPS 77c-79c, consensus 76c
- Notable companies reporting before tomorrow’s open